Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
March 8, 2004
- INF b-1b Effective against Multiple Sclerosis: Nihon Schering Seminar
March 8, 2004
- Annual Business Results
March 8, 2004
- 1st 3 Qtrs Business Results
March 8, 2004
- Lower Cholesterol Reduces Vascular Disease Risk: Banyu Symposium
March 8, 2004
- Sales of Daiichi's Coversyl Beginning to Slacken
March 1, 2004
- Heparinized Saline Kit Market Growing Rapidly
March 1, 2004
- BUSINESS NEWS IN BRIEF
March 1, 2004
- WEBSITE NEWS
March 1, 2004
- Chugai Aims at Top in Priority Fields: Cancer, Nephropathy, Bone
March 1, 2004
- Taisho: Downward Revisions in FY2003 Business Forecast
March 1, 2004
- 1st 3 Qtrs Business Results
March 1, 2004
- 1st Qtrs Business Results
March 1, 2004
- BULLETIN
March 1, 2004
- Sankyo to Conduct Large-scale Clinical Study on Olmesartan
March 1, 2004
- BULLETIN
March 1, 2004
- Tanabe Receives Monkasho Approval for Human ES Cell Study
March 1, 2004
- Meropen IV Gets Remedy of Purulent Meningitis as Add. Indication
March 1, 2004
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 1, 2004
- Chuikyo Approves FY2004 Medical Fee Revision Proposal
March 1, 2004
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…